Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

April 23, 2024

Study Completion Date

April 23, 2024

Conditions
Multiple Sclerosis (MS)Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

ANK-700

Intravenous (IV) infusion

DRUG

Placebo

Intravenous (IV) infusion

Trial Locations (15)

19107

Jefferson University Hospitals, Philadelphia

22180

MS Center of Greater Washington, Vienna

29205

Midlands Neurology & Pain Associates PA, Columbia

33612

University of South Florida - Neurology, Tampa

34105

Aqualane Clinical Research, Naples

35058

North Central Neurology, Cullman

37064

Advanced Neurosciences Institute, Franklin

44195

Cleveland Clinic, Cleveland

66103

University of Kansas Lander Center on Aging/ Neurology, Kansas City

70121

Ochsner Clinic Foundation, New Orleans

75390

University of Texas Southwestern, Dallas

77030

University of Texas Health Science Center, Houston

80045

UC Health Neurosciences Center, Aurora

85013

Barrow Neurological Institute, Phoenix

98405

MultiCare Health System, Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Anokion SA

INDUSTRY

NCT04602390 - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter